NMRA Quote, Financials, Valuation and Earnings

Biogen has a net margin of -- compared to Neumora Therapeutics's net margin of 10.87%. Neumora Therapeutics's return on equity of -- beat Biogen's return on equity of 10.33%.

Neumora Therapeutics has a consensus price target of $6.29, signalling upside risk potential of 730.36%. On the other hand Biogen has an analysts' consensus of $190.50 which suggests that it could grow by 60.3%. Given that Neumora Therapeutics has higher upside potential than Biogen, analysts believe Neumora Therapeutics is more attractive than Biogen.

Neumora Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Biogen has a beta of 0.057, suggesting its less volatile than the S&P 500 by 94.303%.

Neumora Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biogen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Neumora Therapeutics pays -- of its earnings as a dividend. Biogen pays out -- of its earnings as a dividend.

Neumora Therapeutics quarterly revenues are --, which are smaller than Biogen quarterly revenues of $2.5B. Neumora Therapeutics's net income of -$58.8M is lower than Biogen's net income of $266.7M. Notably, Neumora Therapeutics's price-to-earnings ratio is -- while Biogen's PE ratio is 10.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neumora Therapeutics is -- versus 1.79x for Biogen. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of -- compared to Neumora Therapeutics's net margin of 50.24%. Neumora Therapeutics's return on equity of -- beat Johnson & Johnson's return on equity of 30.18%.

Neumora Therapeutics has a consensus price target of $6.29, signalling upside risk potential of 730.36%. On the other hand Johnson & Johnson has an analysts' consensus of $169.84 which suggests that it could grow by 9.87%. Given that Neumora Therapeutics has higher upside potential than Johnson & Johnson, analysts believe Neumora Therapeutics is more attractive than Johnson & Johnson.

Neumora Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.490, suggesting its less volatile than the S&P 500 by 50.995%.

Neumora Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 3.21% to investors and pays a quarterly dividend of $1.24 per share. Neumora Therapeutics pays -- of its earnings as a dividend. Johnson & Johnson pays out 84.05% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Neumora Therapeutics quarterly revenues are --, which are smaller than Johnson & Johnson quarterly revenues of $21.9B. Neumora Therapeutics's net income of -$58.8M is lower than Johnson & Johnson's net income of $11B. Notably, Neumora Therapeutics's price-to-earnings ratio is -- while Johnson & Johnson's PE ratio is 17.19x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neumora Therapeutics is -- versus 4.20x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Pliant Therapeutics has a net margin of -- compared to Neumora Therapeutics's net margin of --. Neumora Therapeutics's return on equity of -- beat Pliant Therapeutics's return on equity of --.

Neumora Therapeutics has a consensus price target of $6.29, signalling upside risk potential of 730.36%. On the other hand Pliant Therapeutics has an analysts' consensus of $10.06 which suggests that it could grow by 589.21%. Given that Neumora Therapeutics has higher upside potential than Pliant Therapeutics, analysts believe Neumora Therapeutics is more attractive than Pliant Therapeutics.

Neumora Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Pliant Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Neumora Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pliant Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Neumora Therapeutics pays -- of its earnings as a dividend. Pliant Therapeutics pays out -- of its earnings as a dividend.

Neumora Therapeutics quarterly revenues are --, which are smaller than Pliant Therapeutics quarterly revenues of --. Neumora Therapeutics's net income of -$58.8M is lower than Pliant Therapeutics's net income of -$49.7M. Notably, Neumora Therapeutics's price-to-earnings ratio is -- while Pliant Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neumora Therapeutics is -- versus 17.58x for Pliant Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Acelyrin has a net margin of -- compared to Neumora Therapeutics's net margin of --. Neumora Therapeutics's return on equity of -- beat Acelyrin's return on equity of --.

Neumora Therapeutics has a consensus price target of $6.29, signalling upside risk potential of 730.36%. On the other hand Acelyrin has an analysts' consensus of $8.00 which suggests that it could grow by 268.66%. Given that Neumora Therapeutics has higher upside potential than Acelyrin, analysts believe Neumora Therapeutics is more attractive than Acelyrin.

Neumora Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Acelyrin has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Neumora Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Acelyrin offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Neumora Therapeutics pays -- of its earnings as a dividend. Acelyrin pays out -- of its earnings as a dividend.

Neumora Therapeutics quarterly revenues are --, which are smaller than Acelyrin quarterly revenues of --. Neumora Therapeutics's net income of -$58.8M is higher than Acelyrin's net income of -$79M. Notably, Neumora Therapeutics's price-to-earnings ratio is -- while Acelyrin's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neumora Therapeutics is -- versus -- for Acelyrin. Usually stocks with elevated PS ratios are considered overvalued.